Several clinical trials are currently ongoing to determine the potential of PD-1/PD-L1 and CTLA-4 targeted therapies in high-grade gliomas yielding conflicting results (Omuro et al., 2017, Reardon et al., 2016). Here, CD274 is linked to central nervous system cancer.